ANXA2 and breast cancer: High expression of exo-AnxA2 levels in BC patients was significantly associated with tumour grade (p < 0.0001), poor overall survival (hazard ratio (HR) 2.802; 95% confidence intervals (CI) = 1.030–7.620; p = 0.0353) and poor disease-free survival (HR 7.934; 95% CI = 1.778–35.398; p = 0.0301).